Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of “Buy” by Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been given an average rating of “Buy” by the nine brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $17.00.

A number of analysts have recently weighed in on IVA shares. Guggenheim dropped their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. UBS Group started coverage on Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective for the company. Leerink Partners assumed coverage on Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. Finally, HC Wainwright set a $24.00 price target on shares of Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th.

Inventiva Price Performance

Shares of IVA opened at $6.75 on Wednesday. Inventiva has a twelve month low of $2.67 and a twelve month high of $7.98. The firm has a fifty day simple moving average of $5.60 and a two-hundred day simple moving average of $5.13.

Hedge Funds Weigh In On Inventiva

Several hedge funds and other institutional investors have recently modified their holdings of IVA. Creative Planning purchased a new stake in Inventiva in the second quarter worth about $32,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after acquiring an additional 9,212 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Inventiva in the 3rd quarter valued at approximately $649,000. NewEdge Advisors LLC purchased a new position in shares of Inventiva in the 3rd quarter valued at approximately $116,000. Finally, UBS Group AG boosted its position in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.